Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23


Abstract submission is now closed

Accepted abstracts are available online

Outcome notifications

Outcome notifications are expected to be made available to first authors by March 2021.

Abstract submission deadlines


Date and time

  • Abstracts
  • Trial in Progress
  • Intent to submit LBA

Wednesday, 3 February 2021
at 21:00 CET (Central European Time) 

Late-breaking abstracts

Final submission deadline*
30 March 2021 at 21:00 CEST (Central European Summer Time)

* A skeleton indicating the type of data that will be available by the late-breaking abstract deadline must be submitted online by the regular abstract deadline 3 February 2021.
Final versions must be submitted by Tuesday, 30 March April 2021 at 21:00 CEST (Central European Summer Time).

Abstract submission categories

  • Early breast cancer: Surgery and radiotherapy
  • Early breast cancer: Neoadjuvant therapy
  • Early breast cancer: Adjuvant therapy
  • Metastatic breast cancer
  • Biomarkers and translational research and precision medicine
  • Immunotherapy
  • Supportive care and survivorship
  • Miscellaneous

Late-breaking abstracts

Late-breaking abstracts may be submitted for high quality, new research findings with implications for clinical practice or understanding of disease processes. The work must not have been previously published in any publication in a peer review setting or presented at a meeting of any other scientific organisation prior to ESMO Breast Cancer 2021.

Only abstracts for which no conclusive data are available at the time of the abstract submission deadline of 3 February 2021 will be considered for late-breaking status.

Trial in Progress abstracts

Trial in Progress (TiP) abstracts in all phases of clinical research (phases I to III) may be submitted to ESMO Breast Cancer 2021.

It is expected that abstracts submitted as Trial in Progress are ongoing trials that have not reached any protocol-specified endpoints for analysis and consequently will only require the completion of two (2) sections:

  • Background
  • Trial design


  • Recruitment must have already begun or have been completed by the abstract submission deadline of 3 February 2021.
  • Abstracts including results or preliminary data will be rejected.
  • Authors of ‘encore’ TiP abstract submissions must supply information regarding the original presentation, indicating the name of the meeting and publication number. The first author will be responsible for obtaining, and, upon request, showing proof that written permission has been obtained from the copyright holder of the original abstract publication(s).
  • Trial in Progress abstracts will be accepted for Poster outcome only.

Abstracts will be reviewed by the ESMO Breast Cancer 2021 Scientific Committee and considered on the merits of the scientific and clinical rationale of the trial.

Publication schedule of accepted abstracts

  1. Abstracts accepted for presentation during ESMO Breast Cancer 2021 (Proffered Paper, Mini Oral and Poster) and for publication in the ESMO Breast Cancer 2021 Abstract Book, will be published online on the ESMO Breast Cancer 2021 website on Monday, 3 May 2021.
  2. Late-breaking abstracts (LBA) accepted for presentation during ESMO Breast Cancer 2021 will be made public on the day of presentation during the official ESMO Breast Cancer 2021 Programme.
  3. Abstracts and LBAs selected for the official ESMO Breast Cancer 2021 Press Programme will be available 10 days before the Congress.


Date and Time

 Abstracts accepted as:

  • Proffered Paper (suffix ‘O’)
  • Mini Oral (suffix ‘O’)
  • Poster (suffix ‘P’)

3 May 2021, 12:00 Central European Summer Time (CEST).

 Late-breaking abstracts (prefix ‘LBA’) 

At the start of the official Congress session during which they are presented

 Abstracts and LBAs selected for the official ESMO Press Programme (additional suffix ‘PR’)

ESMO Press Programme and related abstract publication schedule, will be available 10 days before the Congress.

Presentation of accepted abstracts

The Breast 2021 Scientific Committee will select abstracts for presentation during the Congress and determine the format of the presentations from the following possibilities:

  • Proffered Paper (oral presentation) – Oral presentations by authors presenting original data of superior quality, followed by expert discussion and perspectives.
  • Mini oral – Short presentation by the authors with comment and interactive audience discussion led by an invited expert.
  • Poster – An important method for communicating details of scientific research, posters will be on display for the duration of the Congress.


All accepted abstracts will be published as a supplement to the official ESMO journal Annals of Oncology.

Registration Grants 

A restricted number of Registration Grants to ESMO Breast Cancer 2021 are available, upon application, to first author (= presenter) of candidates under the age of 40 who submit abstracts considered deserving of recognition. Selection will be made by the ESMO Breast Cancer 2021 Scientific Committee on a competitive basis from among the accepted abstracts.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings